ALPA

Alpa Laboratories Financial Results

₹58.10-1.07%
Market cap
₹122 crore
P/E
27.9
P/B
0.66
ROE
8.4%
Dividend yield
1.20%

For the year ended Mar 2018, Alpa Laboratories reported revenue of ₹20 crore and net profit of ₹0 crore, against ₹86 crore and ₹2 crore a year earlier.

Alpa Laboratories annual profit and loss

Financial years, newest first. TTM = trailing twelve months.

Alpa Laboratories annual profit and loss (₹ crore)
ItemMar 2018Mar 2020Mar 2021Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue20869892108112105111
Expenses1983908498106101112
Operating profit13891064-1
Operating margin %4%4%8%9%9%5%4%-1%
Other income334913221510
Interest00000000
Depreciation03112222
Profit before tax3311162126176
Tax %86%36%33%21%19%24%10%26%
Net profit027131720154
EPS (₹)0.000.880.005.987.979.277.132.08
Dividend payout %————————

Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Alpa Laboratories financial results — frequently asked questions

What is Alpa Laboratories' annual revenue and net profit?

For the financial year ended Mar 2018, Alpa Laboratories' revenue was ₹20 crore and net profit ₹0 crore; net profit fell 100.00% from ₹2 crore in Mar 2020.

How fast has Alpa Laboratories grown over three years?

From Mar 2023 to Mar 2018, Alpa Laboratories' revenue grew at a compound annual rate of -39.9%. Past growth does not indicate future results.

What is the EPS of Alpa Laboratories?

Annual EPS for Mar 2018 was ₹0.00.

Are these figures consolidated or standalone?

They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.

Same Data For Peers

Trade Alpa Laboratories With ATS

Track ALPA live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.